Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002117
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Randomized Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine HIVID ddC and Zidovudine AZT in Patients With HIV Infection
Sponsor:
Hoffmann-La Roche
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Randomized Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine HIVID ddC and Zidovudine AZT in Patients With HIV Infection
Status:
COMPLETED
Status Verified Date:
1995-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate the appropriate zalcitabine dideoxycytidine ddC dose and zidovudine AZT schedule for use in combination therapy in patients with HIV infection
Detailed Description:
Patients are randomized to one of four treatment arms ddC is administered at 1 of 2 doses every 8 hours AZT is administered at 1 of 2 doses every 4 hours while awake or every 8 hours
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NV 14257 | None | None | None |